gadolinium-chelate

Phase 2Small molecule

MM.D. Anderson Cancer Center

gadolinium-chelate is one of 135 small molecule programs targeting Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Pancreatic Ductal AdenocarcinomaNot yet recruiting

Breast CancerActive, not recruiting

Glioblastoma, IDH-WildtypeRecruiting

MetastasisPreclinical

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPreclinical

Not yet recruiting

Breast CancerPreclinical

Active, not recruiting

Glioblastoma, IDH-WildtypePhase 2

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

gadolinium-chelate

MM.D. Anderson Cancer Center

Phase 2

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Glioblastoma, IDH-Wildtype

NCT06319027

Q4 2027

PreclinicalRecruiting

Pancreatic Ductal Adenocarcinoma

NCT07705919

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Dutasteride in Treating Patients With Prostate Cancer

Unknown status·UUniversity College London Hospitals·Phase 2·NCT01193855·42 enrolled

Breast Cancer1 trial

Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer

Unknown status·RRoyal Marsden NHS Foundation Trust·N/A·NCT00602316·20 enrolled

Metastasis1 trial

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Completed·MM.D. Anderson Cancer Center·N/A·NCT04870645·15 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT07705919·50 enrolled

Glioblastoma, IDH-wildtype1 trial

Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT06319027·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for gadolinium-chelate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gadolinium-chelate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gadolinium-chelate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

gadolinium-chelate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Prostate Cancer1 trial

Breast Cancer1 trial

Metastasis1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Glioblastoma, IDH-wildtype1 trial

References

Drug Info

Quick Facts

Related News